TG Therapeutics Reports Positive Phase 3 ENHANCE Trial Results for BRIUMVI, Streamlining Dosing
TGTX sits 55% above its 52-week low of $25.28.
Summary
TG Therapeutics announced positive Phase 3 trial results for BRIUMVI, demonstrating that a single Day 1 infusion is bioequivalent to the current two-infusion initiation regimen, simplifying treatment for multiple sclerosis patients.
Key Events · Product Development and Regulatory · TGTX
-
Positive Phase 3 Trial Results
The ENHANCE trial met its primary endpoint, demonstrating bioequivalence for a single 600 mg Day 1 infusion of BRIUMVI compared to the currently approved Day 1 and Day 15 regimen.
-
Streamlined Dosing Regimen
This new regimen eliminates the need for a second infusion visit, potentially accelerating time to treatment and reducing scheduling burdens for patients and healthcare providers.
-
Consistent Safety Profile
Safety and tolerability were consistent with BRIUMVI's established profile, with no new safety signals observed.
-
Supplemental BLA Filing Planned
The company plans to submit a supplemental Biologics License Application (BLA) in the second half of 2026 to seek approval for the consolidated dosing.
Analysis · TGTX · Life Sciences
This filing confirms positive Phase 3 results for BRIUMVI, a key product for TG Therapeutics. The ability to initiate treatment with a single infusion instead of two significantly improves patient convenience and operational efficiency for infusion centers. This enhancement could boost BRIUMVI's competitive position and market adoption, contributing to future revenue growth. The planned supplemental BLA filing in 2H-2026 is the next step towards realizing this benefit.
At the time of this filing, TGTX was trading at $39.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $25.28 to $44.65. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.